IMGO News

After a slow start to the month, the IPO market revved back to life with 13 IPOs coming to market this past week. SPAC activity picked up, with seven blank check IPOs raising $940 million. New filers continued to flood the IPO pipeline, with fourteen IPOs and nine SPACs submitting initial filings.   Italian drug container supplier Stevanato Group (STVN)...read more

Imago BioSciences, a Phase 2 biotech developing small molecules for bone marrow cancer and diseases, raised $134 million by offering 8.4 million shares at $16, the high end of the range of $14 to $16. The company plans to raise an additional $20 million in a concurrent private placement to Pfizer. At pricing, Imago BioSciences commands a fully diluted market value of $556...read more

Imago BioSciences, a Phase 2 biotech developing small molecules for bone marrow cancer and diseases, announced terms for its IPO on Monday. The South San Francisco, CA-based company plans to raise $105 million by offering 7 million shares at a price range of $14 to $16. The company plans to raise an additional $20 million in a concurrent private placement to Pfizer. At the midpoint...read more

Updated Monday, 7/12. After a slow holiday week, 15 IPOs are scheduled to raise nearly $4 billion in the week ahead. A handful of SPACs should also price. Italian drug container supplier Stevanato Group (STVN) plans to raise $900 million at a $6.8 billion market cap. Controlled by its founding family, the profitable company supplies glass vials,...read more